- About us
- Company details
THERA65 develops precision oncology solutions targeting p65BTK, an oncogenic driver of drug resistance in several solid tumors. We address the major clinical problem of resistance to current cancer therapies. Our customers include pharma companies and oncology centers. We develop an aptamer-based PROTAC therapeutic that selectively degrades p65BTK and a companion IVD to identify eligible patients. Our approach uniquely targets the tumor- specific isoform while sparing normal BTK in immune cells.
Year of establishment:
2023
Number of employees:
FROM 3 TO 9 EMPLOYEES
Annual turnover:
Not available
Reference year of turnover:
2025
Export turnover:
Not available
Activities:
Research and experimental development on biotechnology
- Videos
- Catalogue
No videos uploaded
No documents uploaded
- Contact Information
- Business Proposals
Company:
THERA65 S.R.L.
Web site:
Address:
VIA GIOVANNI DE' MEDICI, 61/B
City:
CESANO MADERNO (MB)
Zip Code:
20811
E-commerce:
Social media:
Tag:
No business proposals uploaded
- Map
p65BTK PROTAC
We develop an aptamer-based PROTAC therapeutic that selectively degrades p65BTK and a companion IVD to identify eligible patients. Our approach uniquely targets the tumor specific isoform while sparing normal BTK in immune cells.